Early death in patients with acute promyelocytic leukemia. Proceedings from a live roundtable at the 2010 American Society of Hematology Annual Meeting, December 4-7, 2010, Orlando, Florida.

Martin S. Tallman, Francesco Lo-Coco, Hau C. Kwaan, Miguel A. Sanz, Steven D. Gore

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide, acute promyelocytic leukemia (APL) has become a highly curable malignancy. Approximately 90% of patients achieve complete remission with induction, which generally includes ATRA and an anthracycline-based chemotherapy. Early death, either before treatment is initiated or during induction, has emerged as one of the most critical issues involved in the current care of patients with APL. The main cause of early death in APL is bleeding, often intracranial. It has become increasingly clear that induction therapy should be initiated in patients at the earliest time possible, even before confirmation of the diagnosis of APL has been made. In this roundtable, several experts discuss important insights into the high rate of early death observed in APL. In addition to the importance of rapid diagnosis, the pathophysiology of the coagulopathy associated with APL will be discussed, as will factors that may be predictive of early death and potential interventions to prevent this important limitation to the cure of many, if not most, patients.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalClinical Advances in Hematology and Oncology
Volume9
Issue number2 Suppl 3
Publication statusPublished - Feb 2011

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Remission Induction
Anthracyclines
Cause of Death
Patient Care
Hemorrhage
Drug Therapy
Mortality
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

@article{a15fea6c1a7149bda31d1f8d50f6d9f8,
title = "Early death in patients with acute promyelocytic leukemia. Proceedings from a live roundtable at the 2010 American Society of Hematology Annual Meeting, December 4-7, 2010, Orlando, Florida.",
abstract = "With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide, acute promyelocytic leukemia (APL) has become a highly curable malignancy. Approximately 90{\%} of patients achieve complete remission with induction, which generally includes ATRA and an anthracycline-based chemotherapy. Early death, either before treatment is initiated or during induction, has emerged as one of the most critical issues involved in the current care of patients with APL. The main cause of early death in APL is bleeding, often intracranial. It has become increasingly clear that induction therapy should be initiated in patients at the earliest time possible, even before confirmation of the diagnosis of APL has been made. In this roundtable, several experts discuss important insights into the high rate of early death observed in APL. In addition to the importance of rapid diagnosis, the pathophysiology of the coagulopathy associated with APL will be discussed, as will factors that may be predictive of early death and potential interventions to prevent this important limitation to the cure of many, if not most, patients.",
author = "Tallman, {Martin S.} and Francesco Lo-Coco and Kwaan, {Hau C.} and Sanz, {Miguel A.} and Gore, {Steven D.}",
year = "2011",
month = "2",
language = "English",
volume = "9",
pages = "1--16",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "2 Suppl 3",

}

TY - JOUR

T1 - Early death in patients with acute promyelocytic leukemia. Proceedings from a live roundtable at the 2010 American Society of Hematology Annual Meeting, December 4-7, 2010, Orlando, Florida.

AU - Tallman, Martin S.

AU - Lo-Coco, Francesco

AU - Kwaan, Hau C.

AU - Sanz, Miguel A.

AU - Gore, Steven D.

PY - 2011/2

Y1 - 2011/2

N2 - With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide, acute promyelocytic leukemia (APL) has become a highly curable malignancy. Approximately 90% of patients achieve complete remission with induction, which generally includes ATRA and an anthracycline-based chemotherapy. Early death, either before treatment is initiated or during induction, has emerged as one of the most critical issues involved in the current care of patients with APL. The main cause of early death in APL is bleeding, often intracranial. It has become increasingly clear that induction therapy should be initiated in patients at the earliest time possible, even before confirmation of the diagnosis of APL has been made. In this roundtable, several experts discuss important insights into the high rate of early death observed in APL. In addition to the importance of rapid diagnosis, the pathophysiology of the coagulopathy associated with APL will be discussed, as will factors that may be predictive of early death and potential interventions to prevent this important limitation to the cure of many, if not most, patients.

AB - With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide, acute promyelocytic leukemia (APL) has become a highly curable malignancy. Approximately 90% of patients achieve complete remission with induction, which generally includes ATRA and an anthracycline-based chemotherapy. Early death, either before treatment is initiated or during induction, has emerged as one of the most critical issues involved in the current care of patients with APL. The main cause of early death in APL is bleeding, often intracranial. It has become increasingly clear that induction therapy should be initiated in patients at the earliest time possible, even before confirmation of the diagnosis of APL has been made. In this roundtable, several experts discuss important insights into the high rate of early death observed in APL. In addition to the importance of rapid diagnosis, the pathophysiology of the coagulopathy associated with APL will be discussed, as will factors that may be predictive of early death and potential interventions to prevent this important limitation to the cure of many, if not most, patients.

UR - http://www.scopus.com/inward/record.url?scp=84882490310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882490310&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 1

EP - 16

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 2 Suppl 3

ER -